Adherus AutoSpray Dural Sealant; Adherus AutoSpray ET Dural Sealant
Stryker Leibinger GmbH & Co. KG · Decision date Jul 15, 2026
What did the FDA approve?
FDA records P130014/S022 as a supplement to PMA P130014, with the supplement type “Panel Track”. The recorded decision is approval, dated Jul 15, 2026.
FDA approval order statement
The Adherus AutoSpray Dural Sealant and Adherus AutoSpray ET Dural Sealant are indicated for use in patients who are 13 years of age and older, as an adjunct to standard methods of dural repair, such as sutures, to provide watertight closure during cranial and spinal procedures.
- Regulatory pathway
- PMA supplement
- Supplement type
- Panel Track
- Clinical specialty
- Neurology
- Decision date
- Jul 15, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P130014/S022
- Regulatory pathway
- PMA supplement
- Applicant
- Stryker Leibinger GmbH & Co. KG
- Product code
- NQR
- Decision code
- APPR
- Decision date
- Jul 15, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Sealant, dural.
- Applicant
- Stryker Leibinger GmbH & Co. KG
- Product code
- NQR
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P130014/S021 · Related supplement
Adherus AutoSpray Dural Sealant
P130014/S022 received
Application receipt date recorded by FDA.
P130014/S022 · FDA decision
Panel Track
Timeline entries are records held by MedtechLedger for P130014. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P130014
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Adherus AutoSpray Dural SealantP130014/S021 | Stryker Leibinger GmbH & Co. KG | PMA supplement | Nov 6, 2025 | FDA |
Explore the linked device profile
Other records with product code NQR
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
CraniSeal Dural SealantP220014/S013 | Pramand, LLC | PMA supplement | Oct 1, 2026 | FDA |
SpineSeal Spine SealantP240027/S007 | Pramand, LLC | PMA supplement | Sep 11, 2026 | FDA |
SpineSeal Spine SealantP240027/S006 | Pramand, LLC | PMA supplement | Aug 31, 2026 | FDA |
CraniSeal Dural SealantP220014/S012 | Pramand, LLC | PMA supplement | Aug 5, 2026 | FDA |
CraniSeal Dural SealantP220014/S011 | Pramand, LLC | PMA supplement | Apr 1, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Stryker Leibinger GmbH & Co. KG
- Headquarters
- Not reported
- Brand website
- stryker.com
- FDA applicant address
- Boetzinger Strasse 41, Freiburg, D-7911
Sources and methodology
- Original FDA record: P130014/S022
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



